15-valent pneumococcal conjugate vaccine + DTaP vaccine

This is a **combination vaccine** composed of a *15-valent pneumococcal conjugate vaccine*—designed to provide immunity against 15 serotypes of Streptococcus pneumoniae—and a *DTaP vaccine*, which includes antigens from diphtheria toxoid, tetanus toxoid, and acellular pertussis components. The 15-valent pneumococcal conjugate vaccine (e.g., PCV15) contains polysaccharide antigens from 15 pneumococcal serotypes conjugated to a carrier protein (most commonly CRM197, a genetically detoxified diphtheria toxin), which elicits a T-cell dependent immune response to each included serotype[2][3]. DTaP employs inactivated toxins or protein subunits from Corynebacterium diphtheriae (diphtheria), Clostridium tetani (tetanus), and Bordetella pertussis (pertussis) to stimulate immunity. Mechanistically, each component works by inducing protective antibody responses that facilitate opsonization and neutralization of the respective bacterial pathogens, reducing risk for invasive or toxin-mediated disease[1][2]. Combination vaccines such as this (if available) streamline immunization schedules to improve pediatric vaccination coverage and compliance. While multiple studies have evaluated co-administration of pneumococcal conjugate vaccines and DTaP in separate syringes at different sites, there are currently **no licensed products** combining the two in a single injectable formulation, though this is an area of active research and development[1]. Primary indication: prevention of invasive pneumococcal disease, diphtheria, tetanus, and pertussis in children.